Gaithersburg-based molecular diagnostics company OpGen Inc. went public Tuesday, and saw its shares drop more than 20 percent during the day before closing at $4.85, down nearly 19 percent.
CEO Evan Jones said he’s not concerned. In the world of biotech, making money can take time.
{iframe}http://www.bizjournals.com/washington/blog/2015/05/opgen-ceo-not-worried-after-stock-falls-in-first.html?ana=e_du_pap&s=article_du&ed=2015-05-05&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1430854609{/iframe}